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Abstract
Background: Topical calcineurin inhibitors (TCIs) such as
pimecrolimus and tacrolimus have recently been used for
dermatologic diseases including atopic dermatitis instead of
topical glucocorticoids, because they display comparable efficacy,
but less-frequent side effects. Although even short-term topical
glucocorticoid compromise epidermal permeability barrier
homeostasis, the effects of TCI on barrier function have not yet
been reported. However, viral infections such as eczema
herpeticum and molluscum contagiosum, which could indicate an
impaired skin barrier, continue to occur with TCI use in atopic
dermatitis.
Objectives: We determined here whether TCIs disrupt epidermal
permeability barrier and antimicrobial function, and whether these
effects can be prevented.
Methods and results: In normal humans, topical pimecrolimus
and tacrolimus applied twice-daily for 5 days, delay barrier
recovery without an increase in basal transepidermal water loss
was observed. Co-application of physiologic lipid mixture (PLM)
containing an equimolar ratio of ceramides, cholesterol and free
fatty acids normalized barrier homeostasis in the face of topical
TCIs. In hairless mice, 4 days of TCI treatment also disrupted
barrier function significantly. TCIs-treated epidermis showed the
decrease of epidermal lipid content, lamellar body number and
secretion, and lipid synthesis-related enzymes such as 3-hydroxy-
3-methylglutaryl-CoA (HMG-CoA) reductase, serine-palmitoyl
transferase and fatty acid synthase, implying decreased lipid
synthesis. TCIs also suppressed expression of IL-1a and
antimicrobial peptides, CRAMP and mouse b-defensin 3.
However, these TCI-induced abnormalities can be overridden by
topical replacement with PLM.
Conclusions: Our results demonstrate that TCIs induce negative
effects on the skin barrier including permeability and
antimicrobial functions, which are mediated by decreasing
epidermal lipid synthesis, lamellar body secretion and
antimicrobial peptides expression through suppression of cytokine
such as IL-1a, therefore co-treatment with PLM would be helpful
to overcome these negative effects.
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Introduction
Recently developed topical calcineurin inhibitors (TCIs),
including tacrolimus and pimecrolimus, provide an alterna-
tive to topical glucocorticoids (GCs) for the topical treat-
ment of atopic dermatitis and other many inflammatory
disease due to anti-inflammatory efficacy of comparable to
low-to-mid-potency topical GCs (1) and rare cutaneous
side effects (2,3). While prolonged therapy with topical
GCs can provoke cutaneous side effects, such as skin atro-
phy and increased skin infections (4), and potent topical
GC can compromise barrier function after just 2–3 days of
therapy (5). In spite of their putative, improved safety
profile in comparison to GC, there are lingering concerns
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about the use of immunosuppressive agents in patients
already at increased risk for cutaneous viral infections such
as eczema herpeticum, herpes simplex and molluscum con-
tagiosum (6–9). Moreover, the risk of conversion from
localized herpes simplex infection to eczema herpeticum is
not negligible in patients treated with topical tacrolimus
(10).
When permeability barrier function is damaged by
external insults, such as organic solvents or tape stripping,
barrier homeostasis is restored via accelerated preformed
lamellar bodies (LBs) secretion (11), signalled by changes
in the epidermal Ca2+ gradient, new lipid synthesis, and
later, an increase in DNA synthesis (12–14). Stratum corneum
(SC) lipids composed of an approximately equimolar mix-
ture of cholesterol, free fatty acids and ceramides form SC
intercellular membrane bilayers that mediate permeability
barrier function (13). Synthesis of these lipids after barrier
disruption increases in parallel with increased activity of
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase
(HMG-CoA), fatty acid synthase (FAS) and serine-palmi-
toyl transferase (SPT), the rate-limiting enzymes for choles-
terol, free fatty acids and ceramides, respectively (15). LB
contains polar SC lipid precursors such as glucosylcera-
mide, cholesterol, glycerophospholipids and sphingomyelin,
and the hydrolytic enzymes that convert them to non-polar
SC lipids (14). Therefore, LB secretion and epidermal lipid
synthesis perform important key roles in the restoration of
normal barrier function after barrier disruption.
Antimicrobial peptides (AMPs) play an important role
as antimicrobial effectors on the skin surface, as well as dis-
tal outposts of the innate immune system. In humans, two
main AMP families are b-defensins (hBD1, 2, 3 and 4) and
cathelicidins (LL-37). Murine homologues of hBD2 and
LL-37 are mouse b-defensin 3 (mBD3) and cathelin-related
antimicrobial peptide (CRAMP). Furthermore, hBD2 and
cathelicidins are synthesized and stored in LB, and corre-
lated with permeability barrier function (16–18).
Atopic dermatitis exhibits phenotype-dependent abnor-
malities in both permeability and antimicrobial barrier
function (19). Because the permeability and antimicrobial
barriers are co-regulated and interdependent (20–22),
increased microbial pathogenesis could be linked to the
compromised permeability barrier in atopic dermatitis.
Previous studies have shown that chronic use of topical
GCs negatively impacts epidermal permeability barrier
function both by decreasing epidermal proliferation and
differentiation (23), and by inhibiting synthesis of the three
key epidermal barrier lipids (cholesterol, fatty acids and
ceramides) (5), which mediate barrier function. Moreover,
topical GCs down-regulate the expression of both hBD2
and LL-37 (18). Yet, the GC-induced permeability and
antimicrobial defects can both be largely overcome with
topical mixtures of these three physiological lipids (5,18).
Since epidermal permeability and antimicrobial functions
are intrinsically linked, we hypothesized here that the
increased risk of infection in TCI-treated patients correlates
with abnormal permeability barrier function, as occurs with
topical GCs. We evaluated the mechanisms for the TCI-
induced barrier abnormality, and methods of overcome
TCI’s negative effects.
Materials and methods
Human study
Eight normal volunteers (21–29 years, four males and four
females) for the tacrolimus study and ten normal volunteers
(20–40 years, six males and four females) for the pimecroli-
mus study were recruited. The medical ethical committee of
Yonsei University Wonju College of Medicine approved all
described studies. This study was conducted according to
Declaration of Helsinki Principles. Participants gave written
informed consent. The subjects of each study applied either
0.03% tacrolimus ointment (Astellas Pharma Korea Inc,
Seoul, Korea) or 1% pimecrolimus cream (Elidel, Novartis
AG, Basel, Switzerland) on one side of the volar forearm and
petrolatum or hydrobase as a control base, respectively on
the contralateral side twice daily for 5 days. At 24 h after the
last application, the barrier recovery rate was assessed 3 h
after acute barrier disruption with tape stripping with
D-Squame tape (CuDerm, Dallas, TX, USA) by measuring
transepidermal water loss (TEWL) using Tewameter TM 210
(Courage & Khazaka, Cologne, Germany) (24).
To elucidate whether a physiologic lipid mixture (PLM)
(Triceram, Osmotics Corp., Denver, CO, USA) could
improve TCIs-induced barrier impairment in humans,
eight volunteers for tacrolimus study (21–29 years, four
males and four females) and six for pimecrolimus (21–
26 years, four males and two females) without any skin dis-
eases were treated with either 0.03% tacrolimus or 1%
pimecrolimus cream on both forearms twice daily for
5 days. At 24 h after the last application, PLM was applied
on one forearm and petrolatum as a control base on the
other immediately after tape stripping. Basal TEWL and
barrier recovery rate at 3 and 6 h were measured.
Animal study
Female hairless mice (Skh1 ⁄Hr) were housed in the animal
laboratory of Yonsei University Wonju College of Medi-
cine. About 0.03% tacrolimus (Sigma, St Louis, MO, USA)
with vehicle (propylene glycol:ethanol 7:3 v ⁄ v) or vehicle
alone was applied to the backs of mice twice daily for
4 days (n = 5 in each group). At 24 h after last application,
basal TEWL and SC integrity which was determined by
TEWL after acute barrier disruption with tape stripping
were measured. Barrier recovery rate was determined at 3
and 6 h after tape stripping. Skin specimens were taken
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from all hairless mice and processed for nile red staining,
electron microscopic examination, immunohistochemical
staining and quantitative real time RT-PCR assays.
To assess the effect of PLM on impaired skin barrier by
TCIs in mice, hairless mice were divided into three groups;
petrolatum as a control base alone, pimecrolimus with
petrolatum, and pimecrolimus with PLM (n = 6, 6 and 7,
respectively). PLM or petrolatum was applied 20 min after
1% pimecrolimus (Elidel, Novartis A.G.) treatment twice
daily for 4 days. At 24 h after the last application, skin
specimens from hairless mice were taken for nile red stain-
ing, electron microscopic examination, immunohistochemi-
cal staining and quantitative real time RT-PCR assays.
Nile red staining
Nile red staining to visualize SC intercellular and epidermal
lipids was performed with frozen section. The nile red dye,
9-diethylamino-5H-benzo[a]phenoxazine-5-one (Sigma), is
an excellent vital stain for the detection of intracellular
lipid droplets by fluorescence microscopy because it
interacts and fluoresces in the presence of phospholipids,
cholesterol, cholesteryl esters and triacylglycerols (25).
Electron microscopy and quantitative EM analysis
Samples for electron microscopy (EM) were processed
using both 0.5% ruthenium tetroxide and 2% aqueous
osmium tetroxide postfixation. To exclude subjective bias
in these morphologic studies, we quantitated the number
and secretion of both corneodesmosome (CD) and lamellar
body (LB) in EM pictures using an objective method as
described previously (26). Five EM pictures taken at the
same magnification (·20 000) were analysed and compared
between each groups.
Real time RT-PCR
Isolation of epidermis
Skin samples excised from the treated area were immedi-
ately placed epidermis side downward on Petri dishes. Sub-
cutaneous fat was removed with a scalpel, and then skin
samples were placed epidermis side up onto 10 ml of
10 mm EDTA in PBS, then incubated at 37C for 35 min
to separate epidermis from dermis. Epidermis was scraped
off with a scalpel and total RNA was extracted.
Total RNA preparation and cDNA synthesis
Total RNA was extracted using a monophasic solution of
phenol and guanidine isothiocyanate (TRIzol Reagent; Gib-
co BRL). RNA concentration was determined by UV spec-
trometer at 260 nm. Aliquots (1.0 lg) of RNA from each
sample were reverse transcribed using Moloney murine
leukaemia virus reverse transcriptase (MML-V RTase,
Promega). Briefly, RNA samples were incubated at 80C
for 5 min with molecular biology grade water. After incu-
bation on ice, primer extension and reverse transcription
were performed by adding 1· RT-buffer, 2 mm deoxynu-
cleotide triphosphates (dNTPs), 0.2 pm random hexamer
primer (Promega) and MML-V RTase (2.5 units ⁄ll) in
20 ll reaction volumes. Samples were then incubated at
42C for 45 min before storage at -20C.
Quantitative PCR analysis of gene expression
Expression of specific mRNAs was quantified using a Rotor-
Gene 3000 (Corbett Life Science, Sydney, Australia).
Briefly, 10 ll PCR reactions were set up containing: Quanti-
Tect probe PCR Master mix (Qiagen) in a 2· solution, 8 mm
manganese chloride, 200 lm dNTPs, 1.25 units HotstartTaq
polymerase, and 0.5 pm ⁄ll each probes and primers. About
60 ng of cDNA were used per reaction. All reactions used
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) as a
housekeeping gene, provided as an optimized control probe
labelled with TAMRA (Operon Biotechnologies, Cologne,
Germany), enabling data to be expressed in relation to an
internal reference to allow for differences in sampling. All
fluorogenic probes for genes of interest were labelled with
6-carboxyfluorescein (6-FAM). Data were obtained as Ct
values (the cycle number at which logarithmic PCR plots
cross a calculated threshold line) according to the manufac-
turer’s guidelines and used to determine DCt values (Ct of
target gene)Ct of housekeeping gene) as raw data for gene
expression. Fold change in gene expression was determined
by subtracting DCt values for pimecrolimus-treated samples
from their respective base control (or vehicle)-treated sam-
ples. The resulting DDCt values were then used to calculate
fold change in gene expression as 2DDCt. All reactions were
done in triplicate and results are expressed as the mean of
values from three separate experiments. Samples were ampli-
fied using the primers and probes under the following condi-
tions: 95C for 15 min followed by 45 cycles of 95C for 15 s
and 60C for 1 min.
Primers and probes for PCR reactions
Primer and probe sequences for real-time RT-PCR analyses
were as follows:
HMG-CoA reductase primers (forward: 5¢-CCGAATTG-
TATGTGG CACTG-3¢, reverse: 5¢-GGTGCACGTTCCTTGA
AGAT-3¢, Operon Biotechnologies) and HMG-CoA probe
(5¢-CTTGATGGCAGCC TTGGCAG-3¢, Operon Biotechnol-
ogies); FAS primers (forward: 5¢-CTGAAGAGCCTGGAA-
GATCG-3¢, reverse: 5¢-TGTCACGTTGCC ATGGTACT-3¢,
Operon Biotechnologies) and FAS probe (5¢-TGAGCTTTGC
TG CCGTGTCC-3¢, Operon Biotechnologies); SPT primer
(forward: 5¢-GAGAGATGCTGAAGCGGAAC-3¢, reverse: 5¢-
TGGTATGAGCTGCTGACAGG-3¢, Operon Biotechnolo-
gies) and SPT probe (5¢-TGGGATTTCCTGCTACCCCG-3¢,
Operon Biotechnologies); CRAMP primers (forward: 5¢-
TCIs compromise epidermal permeability barrier
ª 2009 John Wiley & Sons A/S, Experimental Dermatology, 19, 501–510 503
TGAGCCCCAAGGGGACGAGG-3¢, reverse: 5¢-GCCGGGTT
CAGGGTGACTGC-3¢, Operon Biotechnologies) and CRAM
P probe(5¢-GTGGCAAGGCAGAGCGG CAGCT-3¢, Operon
Biotechnologies); mBD3 primers (forward: 5¢-GGCTTCAGT
CATGAGGATCCATTACC-3¢, reverse: 5¢-TGCACCGATTC-
CAGCATCTGCC-3¢, Operon Biotechnologies) and mBD3
probe (5¢-TGGTGGCTGCTGTCTCCACCTGCAGCT-3¢, Operon
Biotechnologies) as an external negative control; and GAPDH
as an internal standard and the housekeeping gene used to
derive DCt values (forward primer 5¢-TGCGACTTCAACAG-
CAACTC-3¢, reverse primer 5¢-ATGTAGGCCATGAGG
TCCAC-3¢, Operon Biotechnologies) and GAPDH probe (5¢-
TCTTCCACCTTCGATGCCGG-3¢, Operon Biotechnologies).
Immunohistochemical staining
Skin specimens were fixed in 10% formalin solution and
embedded in paraffin. Sections of 5 lm thickness were pro-
cessed for immunohistochemical staining of proliferation
cell nuclear antigen (PCNA), IL-1a, mBD3 and CRAMP.
We used primary antibodies for PCNA, IL-1a, mBD3 and
CRAMP (Santa Cruz, CA, USA). After de-paraffinization,
sections were rehydrated sequentially with 100%, 90% and
70% ethanol and incubated for 5 min in 3% H2O2 in Tris-
buffered saline (TBS) to inactivate endogenous peroxidases.
Samples were then blocked for 10 min with blocking serum
solution (DAKO, Carpinteria, CA, USA) and incubated
overnight at 4C with primary antibodies. After several
washes in TBS, they were incubated for 30 min with sec-
ondary biotinylated antibodies. Antigen was detected with
the avidin–biotin complex system (Vector, Burlingame, CA,
USA), according to the manufacturer’s instructions by
using 3,3¢-diaminobenzidine tetrahydrochloride as sub-
strate. Then they were examined under a light microscope.
To quantify the density of IL-1a, three pictures for each
section were taken at a 100· magnification, and were
labelled. An investigator without knowledge of the origin
of the specimen ranked the pictures in order of the inten-
sity of immunostaining (highest intensity: first rank, in
descending order in each). Mann–Whitney test was used
for statistics. A representative picture for each group was
chosen for publication.
Binding of the PCNA primary antibody was detected by
ABC peroxidase from Vector, utilizing diaminobenzidine as
the substrate (Vector, Burlingame, CA, USA). For the
PCNA experiments, stained nuclei were counted as positive
and the number of positive cells per length of basal epider-
mis was calculated.
Statistical analyses
All data are expressed as mean ± SEM. Statistical analyses
were performed using paired and unpaired Student’s t-tests
or Mann–Whitney test for assaying density of immunohis-
tochemical staining.
Results
TCIs disrupt epidermal permeability barrier
homeostasis, and this delayed barrier recovery is
restored by co-treatment with a three-component
mixture of SC lipids in TCI-treated human skin
We first assessed whether TCIs alter permeability barrier
function in normal human skin, even after short-term appli-
cations. While applications of either tacrolimus or pimecroli-
mus twice-daily for 5 days changed neither skin appearance
nor basal TEWL in comparison to control base (data not
shown), both topical pimecrolimus and tacrolimus signifi-
cantly delayed the kinetics of barrier recovery 3 h after acute
barrier disruption by repeated tape stripping (Fig. 1a,b).
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Figure 1. Topical calcineurin inhibitors (TCIs) disrupt epidermal
permeability barrier homeostasis in normal human and mice skin, which
delayed barrier recovery, is restored by co-treatment with physiologic
lipid mixture (PLM) of SC lipids in TCI-treated human skin. In human,
either 0.03% tacrolimus ointment or 1% pimecrolimus cream was
applied on one volar forearm, while petrolatum or hydrobase was
applied as a control base to equivalent contralateral sites of normal
human subjects twice-daily for 5 days. At 24 h after the last
application, barrier recovery was measured 3 h after tape stripping of
the treated skin sites (a, b). PLM or petrolatum was applied on either
tacrolimus- or pimecrolimus-treated human forearms immediately after
acute barrier disruption with tape stripping. Barrier recovery rates were
measured at 3 and 6 h (c, d). In hairless mice, their flanks were treated
with topical 0.03% tacrolimus or vehicle (PG:ethanol = 7:3 v ⁄ v) twice
daily for 4 days. SC integrity (e) and barrier recovery rate at 3 and 6 h
after tape stripping (f) were assessed. Statistical analyses in this and all
subsequent experiments were performed using a paired or unpaired
Student’s t-test. Results in this and subsequent experiments are
expressed as mean ± SEM.
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We next determined whether the three-component mix-
ture of cholesterol, free fatty acids and ceramides improves
skin barrier recovery in TCI-treated human skin, as shown
in the previous work by Kao et al. (5). The PLM was
co-applied to skin sites that were being co-treated with
either pimecrolimus or tacrolimus, immediately after bar-
rier disruption by tape stripping, while petrolatum as a
control base was applied to TCI-treated human sites on the
opposite forearm. PLM normalized the barrier recovery
kinetics at 3 and 6 h after acute barrier disruption in both
pimecrolimus- and tacrolimus-treated skin compared to
petrolatum-treated controls (Fig. 1c,d).
TCIs also impair epidermal permeability barrier
homeostasis in mice
To assess whether hairless mice would provide a suitable
model to elucidate pathomechanisms for the TCI-induced
barrier abnormalities shown in human skin, we next exam-
ined effects of TCIs on hairless mouse skin, treated twice a
day for 4 days with 0.03% tacrolimus or vehicle (PG:etha-
nol = 7:3 v ⁄ v) as control. As in humans, basal TEWL did
not show differences between tacrolimus- and vehicle-trea-
ted sites (data not shown). But SC integrity was compro-
mised in comparison to vehicle-treated skin (Fig. 1e), and
permeability barrier recovery was significantly delayed in
tacrolimus-treated group (Fig. 1f). The correspondent
results between murine and human study suggests that
hairless mice can serve as a suitable model for the mecha-
nistic studies of the skin barrier in TCI-treated skin.
Negative effects of TCIs on permeability barrier
function result from decreased epidermal lipid
production
We next assessed whether the tacrolimus-induced abnor-
mality in permeability barrier function reflects altered epi-
dermal lipid production by several different assays. First,
nile red fluorescence staining of frozen sections of mouse
epidermis demonstrated a global decrease in the lipid con-
tent of epidermis in unfixed biopsies after either tacrolimus
or pimecrolimus treatment (Figs 2a,b and 5a), indicating a
markedly reduction in lipid content in TCI versus vehicle-
treatment skin. We assayed the mRNA expression of three
key enzymes of epidermal lipid synthesis; i.e. 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA), SPT and FAS
to assess whether decreased mRNA levels for these three
key enzymes leads to the TCI-induced reduction in epider-
mal lipid synthesis. Topical tacrolimus treatment decreased
all mRNA levels for all three of these enzymes (Fig. 2c),
and a similar result was shown with pimecrolimus even
though different set of experiment design (Fig. 5b).
To assess whether the TCI-induced reduction in lipid
content results in abnormalities of LB production and ⁄or
secretion, LB morphology and quantification from EM
studies were evaluated. Tacrolimus-treated skin revealed
immature (largely empty) organelle contents and a signifi-
cant decrease in the density of LBs (50% decrease), in
comparison to vehicle-treated skin (Fig. 2d–f). Pimecroli-
mus-treated skin showed the similar changes, including a
decreased density of LB and largely empty organelle con-
tents (Fig. 5c,d).
Lastly, we performed PCNA stain to make sure that
above negative effects of tacrolimus were not due to its
toxic effect. The number of PCNA positive cells was not
different between tacrolimus- and vehicle-treated skins
(data not shown). These results demonstrate that TCIs
lead to a decreased generation of both epidermal lipids
and LB, and a decline in permeability barrier recovery
kinetics.
TCIs also disrupt SC integrity through a decrease
in CD
Intercorneocyte cohesion is critical not only for SC integ-
rity, but also for the epidermal permeability barrier (14,27).
This function is mediated largely by CD, unique intercellu-
lar junctions, modified from epidermal desmosomes (28).
Individual CDs appeared prominently foreshortened and
fragmented (Fig. 2g,h) and its density decreased by about
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 2. Topical tacrolimus impairs barrier homeostasis and SC
integrity not only by inhibiting epidermal lipid synthesis and lamellar
body (LB) formation, but also by decreasing corneodesmosome (CD)
density. Skin biopsy samples were taken from the skin treated with
topical 0.03% tacrolimus (T) or vehicle (PG:ethanol = 7:3 v ⁄ v) (V) twice
daily for 4 days, and then stained with fluorescent nile red to visualize
the overall epidermal lipid content (a, b), and assayed real time RT-PCR
for mRNA level of epidermal lipid synthesis-related enzymes (c), and
processed for electron microscopy (EM) to analysis LBs (large white
arrow, d–f) and CDs (white arrow, g–i). Mag bars = 2 mm in Fig. a,b;
2 lm in Fig. d,e,g, h (FAS: fatty acid synthase, HMG-CoA: HMG-CoA
reductase, SPT: serine-palmitoyl transferase).
TCIs compromise epidermal permeability barrier
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40% (Fig. 2i) in the tacrolimus-treated group, compared to
the vehicle-treated group. EM of pimecrolimus-treated
mice yielded similar results (data not shown). Thus, TCIs
impair SC integrity ⁄ cohesion and barrier homeostasis not
only by inhibiting lipid synthesis, but also by decreasing
CD density.
TCIs decrease AMPs expression
Prior studies have shown that the expression of mBD3 and
CRAMP are changed in parallel with permeability barrier
status (21). Since we show above that TCIs decrease LB
secretion in murine skin, we next assessed whether the
expression of mBD3 and CRAMP decreases in murine epi-
dermis after TCI treatment. While vehicle-treated skin
revealed that expression of both mBD3 and CRAMP
(mouse homologues of hBD2 and LL-37, respectively)
largely localized to the outer epidermis (Fig. 3a,c),
tacrolimus-treated skin showed a marked decrease in im-
munostaining for both AMPs in the outer epidermis
(Fig. 3b,d). Additionally, we measured the mRNA level of
mBD3 and CRAMP. Topical tacrolimus treatment signifi-
cantly decreased mRNA levels for mBD3 and CRAMP
(Fig. 3e). These results suggest that TCIs could also disrupt,
at least in part, the antimicrobial barrier of the SC.
TCIs suppress epidermal expression of IL-1a
When acute barrier disruption occurs, the release and pro-
duction of pro-inflammatory cytokines such as IL-1a, IL-
1b, TNF-a and GM-CSF (29,30), signal a restoration of
impaired barrier function (31,32). Since TCIs suppress
expression of several pro-inflammatory cytokines, we next
assessed IL-1a expression in tacrolimus-treated murine skin
by immunohistochemical staining. Tacrolimus-treated skin
sites showed much lower expression of IL-1a than did
vehicle-treated murine skin (Fig. 4a,b), confirmed by semi-
quantitative analysis of randomly obtained, coded (investi-
gator-blinded) micrographs (see Materials and methods)
(Fig. 4c). These results provide one mechanism whereby
TCIs could cause negative effects on permeability barrier
function; i.e. by suppression of IL-1a-mediated stimulation
of epidermal lipid synthesis.
Co-treatment with a three-component mixture of
physiologic lipids compensates for defective
permeability and antimicrobial barrier
homeostasis in TCI-treated murine skin
It is forementioned that a three-component mixture of top-
ical physiologic lipids overrides TCI-induced abnormalities
in permeability barrier function and SC integrity in human
(Fig. 1c,d). To confirm the above results in detail, we next
assessed whether co-treatment with PLM increased LB pro-
duction and epidermal lipid content, assessed by nile red
staining, EM analysis, and mRNA level of lipid synthesis
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Figure 4. Topical tacrolimus suppresses expression of IL-1a in murine
epidermis. Biopsy specimens from 0.03% tacrolimus (T) or vehicle (V)
(PG:ethanol = 7:3 v ⁄ v) -treated skin sites after 4 days of twice-daily
applications were immunostained with IL-1a (a, b) (tacrolimus: n = 5;
vehicle: n = 4). Ranking (semi-quantitative) analysis (c) of randomly
obtained, coded (investigator-blinded) micrographs was estimated by
the intensity of staining signal (see Materials and methods). Mag
bars = 2 mm.
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Figure 3. Topical tacrolimus decreases expression of antimicrobial
peptides such as mBD3 and CRAMP at the mRNA level in murine
epidermis. Biopsy specimens from 0.03% tacrolimus (T) or vehicle (V)
(PG:ethanol = 7:3 v ⁄ v) -treated skin sites after 4 days of twice-daily
applications were immunostained with for mBD3 (a, b) and CRAMP
(c, d), and assayed by real time RT-PCR for RNA level of mBD3 and
CRAMP in murine epidermis (e). Mag bars = 2 mm.
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rate-related enzymes in pimecrolimus-treated murine skin.
Experimental mice were divided into three subgroup: pime-
crolimus+PLM, pimecrolimus+petrolatum and petrolatum
as a control base alone (as a normal control). PLM or pet-
rolatum was applied 20 min after pimecrolimus treatment
twice daily for 4 days. PLM co-treated epidermis restored
nile red fluorescence in comparison to pimecrolimus plus
petrolatum-treated epidermis (Fig. 5a). In accordance
with above data, co-treatment with PLM also increased
mRNA level of epidermal lipid synthesis-related enzymes,
HMG-CoA reductase, FAS and SPT (Fig. 5b), which were
decreased in TCIs-treated murine skin (Fig. 2c). Moreover,
PLM co-treated skin showed a marked increase in normal
shaped LB density in comparison to petrolatum co-treated
skin (Fig. 5c,d). These results show that barrier replacement
therapy with PLM improves the TCI-induced skin barrier
defect, reinforcing the model that TCIs affect epidermal
permeability barrier function by decreasing epidermal lipid
synthesis. Also co-treatment with PLM increase CD length
compared to pimecrolimus with petrolatum (data not
shown). These results mean that PLM could improve not
only epidermal permeability but also SC integrity of
impaired murine skin by TCIs.
Additionally, we measured mRNA levels of AMPs and
performed immunostaining to assess whether co-treatment
with PLM overcome TCI’s negative effect on the antimicro-
bial barrier function. Co-treatment with PLM increased not
only mRNA levels of CRAMP and mBD3 but also protein
expression of AMPs on the immunostaining in TCIs-trea-
ted murine skin (Fig. 6).
Discussion
Because TCIs such as tacrolimus and pimecrolimus are
potent immunosuppressant and are prescribed mainly for
patient with AD, many dermatologists are concerned about
the vulnerability to cutaneous infection of patients. In fact,
there were some reports associated with cutaneous viral
infections after TCIs treatment, including potentially
life-threatening episodes of eczema herpeticum (6,8,33),
although it seems that the incidence of bacterial skin infec-
tions such as Staphylococcous aureus does not increase
(34,35). In addition, since AD patients at greater risk for
viral dissemination exhibit severely impaired barrier func-
tion (36), and since permeability barrier and antimicrobial
function are co-regulated and interdependent (20,21), we
wanted to know here whether TCI treatment also impairs
permeability barrier and antimicrobial function.
First, we demonstrated that short-term TCIs treatment
does not increase basal TEWL either in human or murine
skin, a very similar result to previous observations with topi-
cal GC (5). However, a significant delay in barrier recovery
after acute barrier disruption was observed both in pimecrol-
imus and tacrolimus groups, another similar result with top-
ical GC (5). The barrier defect could not be ascribed to non-
specific toxicity, because epidermal mitogenesis did not
change, and with the exception of abnormal LB, there was no
evidence of cytotoxicity in TCI-treated skin. The similarities
of the functional abnormalities produced by topical GCs and
TCIs suggested to us that similar pathogenic mechanisms
could be operative. GCs compromise barrier function by
decreasing epidermal lipid synthesis. Hence, we examined
here whether the TCI-induced delay in barrier recovery is
(a) (c)
(b) (d) 
Figure 5. Physiologic lipid mixture (PLM) restores SC intercellular lipids
and epidermal lipid synthesis, and the production of lamellar body (LB)
in murine epidermis treated by topical pimecrolimus. Hairless mice were
divided into three groups; petrolatum as a control base alone (V),
pimecrolimus with petrolatum (P), and pimecrolimus with PLM (P+PLM)
(n = 6, 6, and 7, respectively). PLM or petrolatum was applied 20 min
after 1% pimecrolimus treatment twice daily for 4 days. At 24 h after
the last application, skin specimens were taken for nile red staining (a),
quantitative real time RT-PCR assays for mRNA of lipid synthetic
enzymes (b), electron microscopic examination to analyse LB secretion
and production (black arrows) (c, d). (FAS: fatty acid synthase, HMG-
CoA: HMG-CoA reductase, SPT: serine-palmitoyl transferase) Mag
bars = 2 mm in Fig. a; 2 lm in Fig. c.
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also due to inhibition of lipid production. Using the nile red
stain, an EM study for LB density and real time RT-PCR for
mRNA of the rate-limiting enzymes of epidermal lipid syn-
thesis, we showed that TCIs decrease epidermal lipid produc-
tion, LB secretion, and key enzymes of epidermal lipid
synthesis (HMG-CoA, FAS and SPT). The decline in epider-
mal lipid production could be further attributed to an ante-
cedent decrease of the mRNA of their rate-limiting enzymes
(13–15). Therefore, the TCI-induced permeability barrier
impairment is due to a decrease in LB production and epi-
dermal lipid synthesis due to decreased transcription of
their rate limiting enzymes.
We also explored one mechanism that could explain the
decrease in epidermal lipid synthesis in TCI-treated skin.
TCIs display anti-inflammatory effects through inhibition
of many cytokines including IL-1b, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-8, TNF-a and GM-CSF (37–39). When epidermal
permeability barrier is disrupted, several primary cytokines,
including TNF-a, IL-1a, IL-1ra, IL-1b, IL-6, IL-8 and GM-
CSF, are up-regulated prior to increased epidermal lipid
synthesis (29,30). This increased cytokine expression could
restore barrier function by up-regulating keratinocyte
differentiation and ⁄or proliferation (40,41). However,
cytokine knockout models (TNF-a or IL-1a) suggest that
cytokine ⁄ growth factors could also regulate epidermal lipid
synthesis (42), and IL-1a stimulates epidermal lipid synthe-
sis and normalizes LB structure in aged human skin
(31,32). Transcription of several epidermal lipid synthetic
enzymes is, in turn, regulated by sterol regulatory element-
binding proteins (SREBPs), which modulate cholesterol
and fatty acid synthesis in response to changes in the
cellular concentration of these lipids in epidermis (43).
Some of inflammatory cytokines, including TNF and IL-6,
have been shown to activate SREBP (32,44). These findings
suggest that cytokines may regulate lipid synthesis through
activation of SREBP (32,44). Our data show that TCIs
suppress the expression of IL-1a, a cytokine having an
important role of epidermal lipid enzyme modulation and
repairing impaired permeability barrier. We propose that
the inhibitory effects of TCIs on expression of IL-1a and
perhaps other cytokines could alter epidermal lipid synthe-
sis leading to a barrier abnormality. Like TCIs, GC may
also act on the same mechanism regarding inhibition of
the enzyme expression. But, it is still unclear how pro-
inflammatory cytokines affect epidermal lipid synthesis-
related enzymes at the transcriptional level. Further experi-
ments are needed to assess the molecular mechanism.
Our data showed that TCIs decreased LB secretion and
production. We focused on mBD3 and CRAMP, because
both are sequestered in LB (16,17), and likely secreted into
the SC extracellular domains along with LB derived lipids
(20). Results from immunohistochemistry and real time
RT-PCR in the present study demonstrated that mBD3 and
CRAMP expression in the epidermis are markedly down-
regulated at both the protein and mRNA levels after TCIs
application for 4 days, which is correlated with decreased
LB secretion. AMPs could be influenced by several cyto-
kines such as IL-1 or barrier permeability (21,45). There-
fore, the suppressive effect of TCI on IL-1a would directly
or indirectly impact AMP expression and LBs formation in
parallel by several mechanisms, suggesting that TCIs could
impair both permeability barrier and antimicrobial barrier.
To overcome these negative effects of TCI on the skin
barrier, we applied PLM already adopted in previous topi-
cal GC study (5). Optimal lipid mixture (cholesterol, cera-
mide and fatty acid 3:1:1) has been considered a good
treatment to accelerate barrier repair after disruption by
tape stripping (mechanical), acetone or solvent (chemical)
and GC (46,47). Co-administration of PLM increased not
only epidermal lipid content, LB secretion and epidermal
lipids synthesis-related enzymes but also AMPs level in
150
200
P + PLM (n = 7)
P + petrolatum (n = 6)
P < 0.001 P < 0.001 
mBD3 CRAMP
0
50
100
Real time RT-PCR
%
(a) (b)
(c)
(e)
(d)
Figure 6. Co-treatment with physiologic lipid mixture (PLM) increases
the expression of mRNA and protein of antimicrobial peptides in the
topical pimecrolimus-treated epidermis. PLM or petrolatum as a control
base was applied 20 min after 1% pimecrolimus treatment twice daily
for 4 days on the mice skin. At 24 h after the last application, skin
specimens were taken and immunostained with mBD3 (a, b) and
CRAMP (c, d), and assayed by real time RT-PCR for mRNA level of
mBD3 and CRAMP in murine epidermis (e). (P+V: pimecrolimus plus
petrolatum, P+PLM: pimecrolimus plus PLM). Mag bars = 2 mm.
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TCIs-treated murine skin in this research. Through being
transported across the SC into the stratum granulosum
cells and being mixed with the endogenous pool of lipids
(13), physiological lipids could supplement the lipids or
lipid precursors used as like a fuel for barrier recovery after
acute barrier disruption (such as tape stripping) in TCI-
treated skin, which has a weak ability to synthesis epider-
mal lipids. Barrier replacement therapy thus could prevent
TCI-induced impairment of the permeability and antimi-
crobial barrier. Yet, it has been not known whether the
additional treatment of lipid mixture affects the penetration
and ⁄or bioavailability of TCIs.
Even though many parts of this report were performed
with tacrolimus, the results described in this study could suf-
ficiently represent the negative effects of TCIs on the epider-
mal permeability barrier, based on following points: (a) The
corresponding results from human study using both tacroli-
mus and pimecrolimus and some of mouse study were
shown. Particularly, mouse studies with pimecrolimus (Figs 5
and 6) somewhat showed the correspondence between
tacrolimus and pimecrolimus. (b) Tacrolimus and pimecrol-
imus are known to have the same action mechanism and
very similar pharmacokinetics (except for lipophilicity and
permeation) due to their similar molecular structures. There
are only two chemical structure differences (1,48). (c) We
think the negative effects in this report could be mediated by
calcineurin inhibition itself.
Because of difficulties in obtaining human tissue and
overall similarities, hairless mouse model is often used as a
model for the study of epidermal permeability barrier.
However, hairless mouse skin is more permeable to water
and its SC thickness is less half than that of human SC,
therefore they accordingly have poorer barrier function
(49). Thus, it should be careful to translate the findings in
hairless mouse models to human skin.
In conclusion, our results demonstrate that TCIs-induce
negative effects on the skin barrier including permeability
and antimicrobial functions, which are mediated by
decreasing epidermal lipid synthesis, LB secretion and AMP
expression through suppression of cytokine such as IL-1a,
therefore co-treatment with PLM would be helpful to over-
come these negative effects.
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